Free shipping on all orders over $ 500

AM095 sodium

Cat. No. M7674
AM095 sodium Structure
Synonym:

AM095

Size Price Availability Quantity
5mg USD 110  USD110 In stock
10mg USD 170  USD170 In stock
50mg USD 530  USD530 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

AM095 is a potent and selective, orally bioavailable antagonist of lysophosphatidic acid receptor1 (LPA1). AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50=778 nM) and human A2058 melanoma cells (IC50=233 nM). LPA1 has been shown to be involved in neuropathic pain. AM095 inhibition of LPA1 after spinal cord injury resulted in reduced demyelination and improvement in locomotor recovery.

Chemical Information
Molecular Weight 478.47
Formula C27H23N2NaO5
CAS Number 1345614-59-6
Solubility (25°C) DMSO: ≥ 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Castelino FV, et al. Arthritis Rheum. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.

[2] Swaney JS, et al. J Pharmacol Exp Ther. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.

Related LPL Receptor Products
Sonepcizumab

Sonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).

TC LPA5 4

TC LPA5 4 is a specific non-lipid LPA5 (GPR92) antagonist (IC50=0.8 μM in LPA5-RH7777 cells). Shows selectivity for LPA5 against 80 other screening targets.TC LPA5 4 was shown to inhibit LPA-induced aggregation of isolated human platelets.TC LPA5 4 inhibits proliferation and migration of thyroid cancer cells.

BMS-986278

BMS-986278 is a potent LPA1 antagonist with a Kb of 6.9 nM.

SAR247799

The S1P1 agonist SAR247799 is a biased agonist of the S1P1 sphingosine receptor, preferentially activating G protein signaling over the β-arrestin and internalization pathways.

GLPG2938

GLPG2938 is a potent and selective S1P2 antagonist.GLPG2938 can be used in the study of idiopathic pulmonary fibrosis (IPF).

  Catalog
Abmole Inhibitor Catalog




Keywords: AM095 sodium, AM095 supplier, LPL Receptor, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.